KOD News

Kodiak Sciences to Present at American Chemical Society Fall 2025

PALO ALTO, Calif., Aug. 19, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology company committed to researching, developing and commercializing transformative therapeutics, announced today that senior management will present the Company's...

August 19, 2025Presentation

Kodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results

KOD

PALO ALTO, Calif., Aug. 13, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the second quarter ended June 30, 2025. "Our July 16 Investor R&D Day brought forward compelling new data along with a clear commercial...

August 13, 2025Earnings

Kodiak Sciences Q1 EPS $(1.09) Misses $(0.87) Estimate

KOD

May 14, 2025

Reported Earlier, Kodiak Sciences Highlights Bispecific Protein Innovations And ABC Platform Advancements At ARVO 2025 In Salt Lake City

KOD

May 2, 2025

HC Wainwright & Co. Reiterates Neutral on Kodiak Sciences, Maintains $3 Price Target

KOD

March 31, 2025

Kodiak Sciences Q4 EPS ($0.84) Up From ($1.13) YoY.

KOD

March 27, 2025

Kodiak Sciences Completes Enrollment In Second Registrational Trial Of Tarcocimab In Patients With Diabetic Retinopathy; Topline Clinical Data Of The Confirmatory Registrational Study GLOW2 Expected In Q1 2026

KOD

March 10, 2025

Barclays Maintains Underweight on Kodiak Sciences, Raises Price Target to $4

KOD

November 15, 2024

HC Wainwright & Co. Reiterates Neutral on Kodiak Sciences, Maintains $3 Price Target

KOD

November 15, 2024

Kodiak Sciences Q3 2024 GAAP EPS $(0.84) Beats $(0.87) Estimate

KOD

November 14, 2024